Cogstate (ASX:CGS) said it executed total net sales contracts worth $21.9 million in the June quarter, up from $14 million in the prior corresponding period, according to a Wednesday filing with the Australian bourse.

The company reported $89 million in net sales contracts in fiscal year 2026, representing a 116% increase from $41.3 million in fiscal year 2025, per the filing.

The company enters fiscal year 2027 with $118.5 million in contracted future revenue, reflecting 32% year-on-year growth, with $48.3 million expected to be recognized in the said fiscal year, the filing said.

Clinical trials revenue commitments for fiscal year 2027 rose 58% to $46.1 million, while healthcare revenue remained steady at $2.3 million, the filing added.